NASDAQ:RUBYRubius Therapeutics Stock Price, Forecast & News

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RUBY stock has decreased by 1.5% and is now trading at $6.45. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Rubius Therapeutics.

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Rubius Therapeutics.

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.04. View Rubius Therapeutics' earnings history.

6 Wall Street analysts have issued 12-month price targets for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $28.00. On average, they anticipate Rubius Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View analysts' price targets for Rubius Therapeutics.

Media coverage about RUBY stock has trended extremely negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutRubius Therapeutics.

Some companies that are related to Rubius Therapeutics include Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Translate Bio (TBIO) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Opko Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Dicerna Pharmaceuticals (DRNA), Editas Medicine (EDIT) and Amicus Therapeutics (FOLD).

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.30%), BlackRock Inc. (3.76%), Capital World Investors (2.19%), JPMorgan Chase & Co. (1.46%), State Street Corp (0.82%) and Federated Hermes Inc. (0.75%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Francis M Cuss, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen. View institutional ownership trends for Rubius Therapeutics.

RUBY stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Invesco Ltd., BlackRock Inc., Morgan Stanley, UBS Group AG, Deutsche Bank AG, State of Michigan Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, and Robert Langer. View insider buying and selling activity for Rubius Therapeutics.

RUBY stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Federated Hermes Inc., Russell Investments Group Ltd., Two Sigma Investments LP, Tekla Capital Management LLC, Geode Capital Management LLC, State of Michigan Retirement System, and Two Sigma Advisers LP. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, Francis M Cuss, and Pablo J Cagnoni. View insider buying and selling activity for Rubius Therapeutics.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RUBY stock can currently be purchased for approximately $6.45.

Rubius Therapeutics has a market capitalization of $519.10 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.

The official website for Rubius Therapeutics is www.rubiustx.com.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]